Table I.
Composition CX-Y a | DOTAP (%) | mPEG-DSPE (%) | DPPC (%) | Cholesterol (%) | Size (nm) | Poly-dispersity index | Zeta potential (mV) |
---|---|---|---|---|---|---|---|
C0-0 | 0 | 0 | 30 | 50 | 126 | 0.04 | 4.1 |
C5-0 | 5 | 0 | 25 | 50 | 128 | 0.06 | 17.5 |
C10-0 | 10 | 0 | 20 | 50 | 133 | 0.07 | 21.8 |
C20-0 | 20 | 0 | 10 | 50 | 132 | 0.07 | 35.7 |
C40-0 | 40 | 0 | 0 | 40 | 135 | 0.09 | 46.2 |
C50-0 | 50 | 0 | 0 | 30 | 131 | 0.11 | 56.2 |
C20-1 | 20 | 1 | 9 | 50 | 133 | 0.07 | 35.4 |
C20-2 | 20 | 2 | 8 | 50 | 136 | 0.09 | 32.8 |
C20-5 | 20 | 5 | 5 | 50 | 140 | 0.09 | 30.9 |
C40-1 | 40 | 1 | 0 | 39 | 136 | 0.10 | 45.4 |
C40-2 | 40 | 2 | 0 | 38 | 137 | 0.08 | 44.4 |
C40-3.5 | 40 | 3.5 | 0 | 36.5 | 140 | 0.14 | 42.1 |
C40-5 | 40 | 5 | 0 | 35 | 142 | 0.06 | 40.8 |
C40-7 | 40 | 7 | 0 | 33 | 142 | 0.16 | 39.3 |
All formulations contained 1% rhodamine-labeled DOPE and 19% DOPE
a X = mol.% DOTAP, Y = mol.% PEG